がん性疼痛管理の世界市場：規模、予測、産業動向、成長、シェア、展望、インフレの影響、機会、企業分析（2023年～2030年）

世界のがん性疼痛管理の市場規模は、2030年までに78億米ドル以上に達し、2022年～2030年の予測期間中にCAGRで5.25%の成長が予測されています。

がん長期生存者数の増加や、世界的に高齢者におけるがん有病率が高まっていることから、がんに関連した痛みを抱えて生活する人の数は増加傾向にあります。また、がん治療の進歩により、進行がんでも長生きできるようになり、関連した痛みを抱える人の数がさらに増加しています。

当レポートでは、世界のがん性疼痛管理市場について調査し、市場力学、SWOT分析、治療・薬剤タイプ・適応疾患・国別の市場シェア分析、新たな治療法、企業分析等に関する情報を提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 SWOT分析

• 強み
• 弱み
• 機会
• 脅威

第6章 ポーターのファイブフォース

• 買い手の交渉力
• 供給企業の交渉力
• 競合の度合い
• 新規参入者の脅威
• 代替品の脅威

第7章 疾患の背景と概要

• イントロダクション
• 病因とタイプ
• がん性疼痛分類システム
• がん性疼痛病態生理
• がん性疼痛症候群
• 痛みの臨床症状と評価

第8章 治療と管理

第9章 がん性疼痛管理市場 - 10の主要市場

第10章 がん性疼痛の疫学と患者数

• がん患者
• がん患者：タイプ別
• がん患者：ジェンダー別
• がん患者：死亡率別

第11章 市場シェア分析 - 世界のがん性疼痛管理

• 治療別
• 薬剤タイプ別
• 適応疾患別
• 国別

第12章 治療 - 世界のがん性疼痛管理

• 免疫療法
• 放射線治療
• 化学療法
• ホルモン療法
• 標的療法
• 阻害剤
• 外科手術
• その他

第13章 薬剤タイプ - 世界のがん性疼痛管理

• オピオイド
• 非オピオイド
• 神経ブロッカー

第14章 適応疾患 - 世界のがん性疼痛管理

• 肺がん
• 大腸がん
• 乳がん
• 前立腺がん
• 血液がん
• その他

第15章 国 - 世界のがん性疼痛管理

• 米国
• 英国
• 日本
• フランス
• ドイツ
• イタリア
• スペイン
• サウジアラビア
• 中国
• 韓国

第16章 新たな治療法

• 主要なクロス競合
• Tetrodotoxin: WexPharma
• Resiniferatoxin: Sorrento Therapeutics
• QIXLEEF: Tetra Bio-Pharma

第17章 企業分析

• Daiichi Sankyo Co., Ltd.
• Hisamitsu Pharmaceutical Co., Inc.
• Orexo AB
• Pfizer Inc
• Teva Pharmaceutical Industries Limited
• Sanofi
• Johnson & Johnson
• Eli Lilly

List of Figures

• Figure-01: Global - Cancer Pain Management Market (Billion US$), 2018 - 2022
• Figure-02: Global - Forecast for Cancer Pain Management Market (Billion US$), 2023 - 2030
• Figure-03: Treatment - Immunotherapy Market (Million US$), 2018 - 2022
• Figure-04: Treatment - Forecast for Immunotherapy Market (Million US$), 2023 - 2030
• Figure-05: Treatment - Radiotherapy Market (Million US$), 2018 - 2022
• Figure-06: Treatment - Forecast for Radiotherapy Market (Million US$), 2023 - 2030
• Figure-07: Treatment - Chemotherapy Market (Million US$), 2018 - 2022
• Figure-08: Treatment - Forecast for Chemotherapy Market (Million US$), 2023 - 2030
• Figure-09: Treatment - Hormone Therapy Market (Million US$), 2018 - 2022
• Figure-10: Treatment - Forecast for Hormone Therapy Market (Million US$), 2023 - 2030
• Figure-11: Treatment - Targeted Therapies Market (Million US$), 2018 - 2022
• Figure-12: Treatment - Forecast for Targeted Therapies Market (Million US$), 2023 - 2030
• Figure-13: Treatment - Inhibitors Market (Million US$), 2018 - 2022
• Figure-14: Treatment - Forecast for Inhibitors Market (Million US$), 2023 - 2030
• Figure-15: Treatment - Surgery Market (Million US$), 2018 - 2022
• Figure-16: Treatment - Forecast for Surgery Market (Million US$), 2023 - 2030
• Figure-17: Treatment - Others Market (Million US$), 2018 - 2022
• Figure-18: Treatment - Forecast for Others Market (Million US$), 2023 - 2030
• Figure-19: Drug Type - Opioids Market (Million US$), 2018 - 2022
• Figure-20: Drug Type - Forecast for Opioids Market (Million US$), 2023 - 2030
• Figure-21: Drug Type - Non-Opioids Market (Million US$), 2018 - 2022
• Figure-22: Drug Type - Forecast for Non-Opioids Market (Million US$), 2023 - 2030
• Figure-23: Drug Type - Nerve Blockers Market (Million US$), 2018 - 2022
• Figure-24: Drug Type - Forecast for Nerve Blockers Market (Million US$), 2023 - 2030
• Figure-25: Disease Indication - Lung Cancer Market (Million US$), 2018 - 2022
• Figure-26: Disease Indication - Forecast for Lung Cancer Market (Million US$), 2023 - 2030
• Figure-27: Disease Indication - Colorectal Cancer Market (Million US$), 2018 - 2022
• Figure-28: Disease Indication - Forecast for Colorectal Cancer Market (Million US$), 2023 - 2030
• Figure-29: Disease Indication - Breast Cancer Market (Million US$), 2018 - 2022
• Figure-30: Disease Indication - Forecast for Breast Cancer Market (Million US$), 2023 - 2030
• Figure-31: Disease Indication - Prostate Cancer Market (Million US$), 2018 - 2022
• Figure-32: Disease Indication - Forecast for Prostate Cancer Market (Million US$), 2023 - 2030
• Figure-33: Disease Indication - Blood Cancer Market (Million US$), 2018 - 2022
• Figure-34: Disease Indication - Forecast for Blood Cancer Market (Million US$), 2023 - 2030
• Figure-35: Disease Indication - Others Market (Million US$), 2018 - 2022
• Figure-36: Disease Indication - Forecast for Others Market (Million US$), 2023 - 2030
• Figure-37: United States - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-38: United States - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-39: United States - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-40: United States - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-41: United States - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-42: United States - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-43: United States - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-44: United States - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-45: United States - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-46: United States - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-47: United States - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-48: United States - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-49: United States - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-50: United States - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-51: United Kingdom - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-52: United Kingdom - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-53: United Kingdom - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-54: United Kingdom - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-55: United Kingdom - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-56: United Kingdom - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-57: United Kingdom - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-58: United Kingdom - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-59: United Kingdom - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-60: United Kingdom - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-61: United Kingdom - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-62: United Kingdom - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-63: United Kingdom - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-64: United Kingdom - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-65: Japan - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-66: Japan - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-67: Japan - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-68: Japan - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-69: Japan - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-70: Japan - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-71: Japan - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-72: Japan - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-73: Japan - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-74: Japan - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-75: Japan - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-76: Japan - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-77: Japan - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-78: Japan - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-79: France - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-80: France - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-81: France - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-82: France - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-83: France - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-84: France - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-85: France - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-86: France - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-87: France - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-88: France - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-89: France - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-90: France - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-91: France - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-92: France - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-93: Germany - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-94: Germany - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-95: Germany - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-96: Germany - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-97: Germany - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-98: Germany - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-99: Germany - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-100: Germany - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-101: Germany - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-102: Germany - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-103: Germany - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-104: Germany - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-105: Germany - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-106: Germany - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-107: Italy - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-108: Italy - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-109: Italy - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-110: Italy - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-111: Italy - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-112: Italy - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-113: Italy - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-114: Italy - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-115: Italy - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-116: Italy - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-117: Italy - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-118: Italy - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-119: Italy - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-120: Italy - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-121: Spain - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-122: Spain - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-123: Spain - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-124: Spain - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-125: Spain - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-126: Spain - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-127: Spain - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-128: Spain - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-129: Spain - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-130: Spain - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-131: Spain - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-132: Spain - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-133: Spain - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-134: Spain - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-135: Saudi Arabia - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-136: Saudi Arabia - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-137: Saudi Arabia - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-138: Saudi Arabia - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-139: Saudi Arabia - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-140: Saudi Arabia - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-141: Saudi Arabia - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-142: Saudi Arabia - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-143: Saudi Arabia - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-144: Saudi Arabia - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-145: Saudi Arabia - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-146: Saudi Arabia - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-147: Saudi Arabia - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-148: Saudi Arabia - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-149: China - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-150: China - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-151: China - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-152: China - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-153: China - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-154: China - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-155: China - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-156: China - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-157: China - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-158: China - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-159: China - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-160: China - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-161: China - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-162: China - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-163: Korea - Cancer Incidence Per Lakh of Total Population (Number), 2018 - 2022
• Figure-164: Korea - Forecast for Cancer Incidence Per Lakh of Total Population (Number), 2023 - 2030
• Figure-165: Korea - Gender Cancer Patients (Thousand), 2018 - 2022
• Figure-166: Korea - Forecast for Gender Cancer Patients (Thousand), 2023 - 2030
• Figure-167: Korea - Male Cancer Patients (Thousand), 2018 - 2022
• Figure-168: Korea - Forecast for Male Cancer Patients (Thousand), 2023 - 2030
• Figure-169: Korea - Female Cancer Patients (Thousand), 2018 - 2022
• Figure-170: Korea - Forecast for Female Cancer Patients (Thousand), 2023 - 2030
• Figure-171: Korea - Mortality Cancer Patients (Thousand), 2018 - 2022
• Figure-172: Korea - Forecast for Mortality Cancer Patients (Thousand), 2023 - 2030
• Figure-173: Korea - Cancer Pain Management Drug Price Per Capita (US$), 2018 - 2022
• Figure-174: Korea - Forecast for Cancer Pain Management Drug Price Per Capita (US$), 2023 - 2030
• Figure-175: Korea - Cancer Pain Management Market (Million US$), 2018 - 2022
• Figure-176: Korea - Forecast for Cancer Pain Management Market (Million US$), 2023 - 2030
• Figure-177: Daiichi Sankyo Co., Ltd. - Global Revenue (Billion US$), 2018 - 2022
• Figure-178: Daiichi Sankyo Co., Ltd. - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-179: Hisamitsu Pharmaceutical Co., Inc. - Global Revenue (Billion US$), 2018 - 2022
• Figure-180: Hisamitsu Pharmaceutical Co., Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-181: Orexo AB - Global Revenue (Billion US$), 2018 - 2022
• Figure-182: Orexo AB - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-183: Pfizer Inc - Global Revenue (Billion US$), 2018 - 2022
• Figure-184: Pfizer Inc - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-185: Teva Pharmaceutical Industries Limited - Global Revenue (Billion US$), 2018 - 2022
• Figure-186: Teva Pharmaceutical Industries Limited - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-187: Sanofi - Global Revenue (Billion US$), 2018 - 2022
• Figure-188: Sanofi - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-189: Johnson & Johnson - Global Revenue (Billion US$), 2018 - 2022
• Figure-190: Johnson & Johnson - Forecast for Global Revenue (Billion US$), 2023 - 2030
• Figure-191: Eli Lilly - Global Revenue (Billion US$), 2018 - 2022
• Figure-192: Eli Lilly - Forecast for Global Revenue (Billion US$), 2023 - 2030

List of Tables

• Table-01: Global - Cancer Patients - 10 MM Population (Number), 2018 - 2022
• Table-02: Global - Forecast for Cancer Patients - 10 MM Population (Number), 2023 - 2030
• Table-03: Global - Cancer Patients by Type, 2020 - 10 MM Population (Number), 2018 - 2022
• Table-04: Global - Forecast for Cancer Patients by Type, 2020 - 10 MM Population (Number), 2023 - 2030
• Table-05: Global - Cancer Patients by Male - 10 MM Population (Number), 2018 - 2022
• Table-06: Global - Forecast for Cancer Patients by Male - 10 MM Population (Number), 2023 - 2030
• Table-07: Global - Cancer Patients by Female - 10 MM Population (Number), 2018 - 2022
• Table-08: Global - Forecast for Cancer Patients by Female - 10 MM Population (Number), 2023 - 2030
• Table-09: Global - Cancer Patients by Mortality Rate - 10 MM Population (Number), 2018 - 2022
• Table-10: Global - Forecast for Cancer Patients by Mortality Rate - 10 MM Population (Number), 2023 - 2030
• Table-11: Global - Cancer Pain Management Market Share by Treatment (Percent), 2018 - 2022
• Table-12: Global - Forecast for Cancer Pain Management Market Share by Treatment (Percent), 2022 - 2030
• Table-13: Global - Cancer Pain Management Market Share by Drug Type (Percent), 2018 - 2022
• Table-14: Global - Forecast for Cancer Pain Management Market Share by Drug Type (Percent), 2022 - 2030
• Table-15: Global - Cancer Pain Management Market Share by Disease Indication (Percent), 2018 - 2022
• Table-16: Global - Forecast for Cancer Pain Management Market Share by Disease Indication (Percent), 2022 - 2030
• Table-17: Global - Cancer Pain Management Market Share by Country (Percent), 2018 - 2022
• Table-18: Global - Forecast for Cancer Pain Management Market Share by Country (Percent), 2022 - 2030
• Table-19: United States - Cancer Patients by Type, 2020
• Table-20: Korea - Cancer Patients by Type, 2020
• Table-21: United Kingdom - Cancer Patients by Type, 2020
• Table-22: Japan - Cancer Patients by Type, 2020
• Table-23: France - Cancer Patients by Type, 2020
• Table-24: Germany - Cancer Patients by Type, 2020
• Table-25: Italy - Cancer Patients by Type, 2020
• Table-26: Spain - Cancer Patients by Type, 2020
• Table-27: Saudi Arabia - Cancer Patients by Type, 2020
• Table-28: China - Cancer Patients by Type, 2020

Global Cancer Pain Management Market is predicted to hit over US$ 7.80 Billion by 2030 according to Renub Research. Pain is a common and dreaded symptom experienced by individuals undergoing cancer treatment and long-term cancer survivors. Cancer pain can result from the disease itself, its treatments, or a combination of both and it may be acute or chronic, with some individuals experiencing pain long after treatment has ended. The number of people living with cancer-related pain is on the rise, due to the increasing number of long-term cancer survivors and the growing prevalence of cancer in older populations worldwide. With advances in cancer treatments, people are now living longer with advanced cancer, further contributing to the growing number of individuals with cancer-related pain.

The growing incidence of cancer-related pain and the effects of the opioid epidemic on the management of chronic pain have renewed efforts to develop new pain medications that are not addictive, as well as non-drug therapies for managing chronic pain. There is increasing recognition of the need for greater accessibility to pain management medications, which is driving the consumption and acceptance of these drugs over other therapeutic options. Consequently, the high levels of awareness, ease of access, fast-acting nature, and cost-effectiveness of pain management medications have made them a preferred choice over other therapy options.

Cancer Pain Management Market is expanding growth at a CAGR of 5.25% during the forecast period 2022 to 2030

Despite the existing treatment options, the cancer pain management industry is constantly looking for newer and more effective ways to manage pain in cancer patients. Key manufacturers in the industry are exploring the use of the network model for research and development to come up with innovative treatment options. Ongoing research and development efforts help businesses analyze new treatment combinations and their effectiveness in pain management. There is a shift in the industry towards developing personalized drugs, biologics, and quick-dose lifestyle medicines, which make up over 70% of the medications currently in development. The focus is no longer solely on managing symptoms, but on amending the disease itself. Manufacturers are also moving away from chemical-based medications and towards biologic products-based therapeutics. Sympathetic administrative reform is also helping to facilitate the development of novel and effective pain management medications. The Cancer Pain Management Market is valued at US$ 5.18 Billion in the year 2022.

Targeted Therapies is Fastest growing segment in the Cancer Pain Management Industry

By Treatment, Cancer Pain Management Market is divided into Inhibitors, Surgery Immunotherapy, Radiotherapy, Hormone Therapy, Chemotherapy, Targeted Therapies, and Others. Targeted therapies are an important and rapidly evolving field in cancer treatment, and they may play a significant role in managing pain associated with cancer. Targeted therapies are medications that are specifically designed to target the molecular pathways involved in the growth and spread of cancer cells.

By inhibiting the activity of certain proteins or molecules that promote cancer cell growth, targeted therapies can help to reduce the size of tumors and slow down their growth. The advantage of these therapies is that they typically spare normal cells from damage. Targeted therapies may also be used in combination with other treatments, such as chemotherapy, radiation therapy, or surgery, to manage pain associated with cancer. The development of new targeted therapies is an active area of research within the cancer pain management industry, with the aim of improving outcomes and quality of life for cancer patients.

Opioids Reported Foremost Market Stake in 2023

By Drug Type, Cancer Pain Management Market is sub-divided into Opioids, Non-Opioids and Nerve Blockers. Opioids drug are a category of medications frequently utilized to manage pain in cancer patients. These drugs operate by binding to particular receptors in the brain and spinal cord, which can alleviate pain. Opioids are effective for treating both short-term and long-term pain, and they can be administered in various forms, including tablets, patches, and injections.

However, their use should be approached with caution and personalized to each patient's unique requirements and situation, as opioids have potential risks and side effects. Healthcare providers should collaborate closely with their patients to design a thorough pain management strategy that evaluates the advantages and disadvantages of all possible options. Despite their risks, opioids continue to play a vital role in the cancer pain management industry.

Lung Cancer is projected to dominate the Disease Indication segment of Pain Management Market Revenue

By Disease Indication, Cancer Pain Management Market is classified into Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. The lung cancer segment was the leading disease indication in the cancer pain market and is predicted to maintain its dominance throughout the forecast period. This is attributed to the rising incidence of lung cancer, high prevalence of pain associated with lung cancer, and the availability of effective cancer pain analgesics for treating lung cancer. However, the breast cancer segment is anticipated to experience significant market growth during the forecast period, owing to the increasing prevalence of breast cancer and greater adoption of pain analgesics in breast cancer treatment.

United States of America is estimated to have the Largest Market Share for Cancer Pain Management Market

By Country, Cancer Pain Management Market is break up into 10 major markets: United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China and Korea. The cancer pain management industry in the United States is a crucial component of the global market. It is among the largest markets for cancer pain management worldwide, propelled by various factors such as the high incidence of cancer in the nation, increased awareness about the significance of pain management in cancer treatment, and access to advanced medical technologies and therapies. Furthermore, the market is reinforced by a well-established healthcare infrastructure, reimbursement policies, and government initiatives to enhance cancer care and pain management.

This industry is also highly dynamic, with a constant evolution of novel drugs and therapies, and has enormous growth potential in the upcoming years. As the importance of pain management in cancer care continues to gain recognition, and new drugs and therapies are developed, the United States cancer pain management market is poised for significant expansion.

Key Player Analysis

There are several leading competitors contending in Cancer pain management 10MM market. Some of the notable players in the industry include Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson and Eli Lilly.

Renub Research latest report "Cancer Pain Management 10MM Industry, Forecast By Treatment (Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy, Targeted Therapies, Inhibitors, Surgery, Others), Drug Type (Opioids, Non-Opioids, Nerve Blockers), Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others), Country (United States, United Kingdom, Japan, France, Germany, Italy, Spain, Saudi Arabia, China, Korea), Companies (Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson, Eli Lilly)" provides a detailed analysis of Cancer Pain Management 10MM Industry.

Treatment - Market has been covered from 8 viewpoints:

1. Immunotherapy

2. Radiotherapy

3. Chemotherapy

4. Hormone Therapy

5. Targeted Therapies

6. Inhibitors

7. Surgery

8. Others

Drug Type - Market has been covered from 3 viewpoints:

1. Opioids

2. Non-Opioids

3. Nerve Blockers

Disease Indication - Market has been covered from 6 viewpoints:

1. Lung Cancer

2. Colorectal Cancer

3. Breast Cancer

4. Prostate Cancer

5. Blood Cancer

6. Others

Country - Market has been covered from 10 viewpoints:

1. United States

2. United Kingdom

3. Japan

4. France

5. Germany

6. Italy

7. Spain

8. Saudi Arabia

9. China

10. Korea

Company Insights:

• Overview
• Recent Development
• Financial Insight

Companies Covered:

1. Daiichi Sankyo Co., Ltd.

2. Hisamitsu Pharmaceutical Co., Inc.

3. Orexo AB

4. Pfizer Inc

5. Teva Pharmaceutical Industries Limited

6. Sanofi

7. Johnson & Johnson

8. Eli Lilly

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. SWOT Analysis-Coronary Artery Disease Market

• 5.1 Strength
• 5.2 Weakness
• 5.3 Opportunity
• 5.4 Threat

6. Porter's Five Forces

• 6.1 Bargaining Power of Buyers
• 6.2 Bargaining Power of Suppliers
• 6.3 Degree of Competition
• 6.4 Threat of New Entrants
• 6.5 Threat of Substitutes

7. Disease Background and Overview

• 7.1 Introduction
• 7.2 Etiology and Types
• 7.3 Cancer Pain Classification Systems
  • 7.3.1 International Association for the Study of Pain (IASP) Taxonomy
  • 7.3.2 ICD-11
  • 7.3.3 Edmonton Classification System for Cancer Pain (ECS-CP)
• 7.4 Cancer Pain Pathophysiology
• 7.5 Cancer Pain Syndromes
• 7.6 Clinical Presentation and Assessment of Pain

8. Treatment and Management

• 8.1 NCCN Guidelines
• 8.2 ESMO Clinical Practice Guidelines (2018)
• 8.3 Spanish Guidelines
• 8.4 Canadian Recommendations for the Management of Breakthrough Cancer Pain (BTCP)
• 8.5 Multimodal Personalized Management of Cancer Pain

9. Cancer Pain Management Market - 10 Major Markets

10. Cancer Pain Epidemiology and Patient Population

• 10.1 Cancer Patients - 10 MM
• 10.2 Cancer Patients by Type, 2020 - 10 MM
• 10.3 Cancer Patients by Gender - 10 MM
• 10.4 Cancer Patients by Mortality Rate - 10 MM

11. Market Share Analysis - Global Cancer Pain Management

• 11.1 By Treatment
• 11.2 By Drug Type
• 11.3 By Disease Indication
• 11.4 By Country

12. Treatment - Global Cancer Pain Management 10MM

• 12.1 Immunotherapy
• 12.2 Radiotherapy
• 12.3 Chemotherapy
• 12.4 Hormone Therapy
• 12.5 Targeted Therapies
• 12.6 Inhibitors
• 12.7 Surgery
• 12.8 Others

13. Drug Type - Global Cancer Pain Management 10 MM

• 13.1 Opioids
• 13.2 Non-Opioids
• 13.3 Nerve Blockers

14. Disease Indication - Global Cancer Pain Management 10 MM

• 14.1 Lung Cancer
• 14.2 Colorectal Cancer
• 14.3 Breast Cancer
• 14.4 Prostate Cancer
• 14.5 Blood Cancer
• 14.6 Others

15. Country - Global Cancer Pain Management 10 MM

• 15.1 United States
  • 15.1.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.1.2 By Gender - Cancer Patients
    • 15.1.2.1 Male
    • 15.1.2.2 Female
  • 15.1.3 By Type - Cancer Patients, 2020
  • 15.1.4 By Mortality - Cancer Patients
  • 15.1.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.1.6 Market Analysis
• 15.2 United Kingdom
  • 15.2.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.2.2 By Gender - Cancer Patients
    • 15.2.2.1 Male
    • 15.2.2.2 Female
  • 15.2.3 By Type - Cancer Patients, 2020
  • 15.2.4 By Mortality - Cancer Patients
  • 15.2.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.2.6 Market Analysis
• 15.3 Japan
  • 15.3.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.3.2 By Gender - Cancer Patients
    • 15.3.2.1 Male
    • 15.3.2.2 Female
  • 15.3.3 By Type - Cancer Patients, 2020
  • 15.3.4 By Mortality - Cancer Patients
  • 15.3.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.3.6 Market Analysis
• 15.4 France
  • 15.4.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.4.2 By Gender - Cancer Patients
    • 15.4.2.1 Male
    • 15.4.2.2 Female
  • 15.4.3 By Type - Cancer Patients, 2020
  • 15.4.4 By Mortality - Cancer Patients
  • 15.4.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.4.6 Market Analysis
• 15.5 Germany
  • 15.5.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.5.2 By Gender - Cancer Patients
    • 15.5.2.1 Male
    • 15.5.2.2 Female
  • 15.5.3 By Type - Cancer Patients, 2020
  • 15.5.4 By Mortality - Cancer Patients
  • 15.5.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.5.6 Market Analysis
• 15.6 Italy
  • 15.6.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.6.2 By Gender - Cancer Patients
    • 15.6.2.1 Male
    • 15.6.2.2 Female
  • 15.6.3 By Type - Cancer Patients, 2020
  • 15.6.4 By Mortality - Cancer Patients
  • 15.6.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.6.6 Market Analysis
• 15.7 Spain
  • 15.7.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.7.2 By Gender - Cancer Patients
    • 15.7.2.1 Male
    • 15.7.2.2 Female
  • 15.7.3 By Type - Cancer Patients, 2020
  • 15.7.4 By Mortality - Cancer Patients
  • 15.7.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.7.6 Market Analysis
• 15.8 Saudi Arabia
  • 15.8.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.8.2 By Gender - Cancer Patients
    • 15.8.2.1 Male
    • 15.8.2.2 Female
  • 15.8.3 By Type - Cancer Patients, 2020
  • 15.8.4 By Mortality - Cancer Patients
  • 15.8.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.8.6 Market Analysis
• 15.9 China
  • 15.9.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.9.2 By Gender - Cancer Patients
    • 15.9.2.1 Male
    • 15.9.2.2 Female
  • 15.9.3 By Type - Cancer Patients, 2020
  • 15.9.4 By Mortality - Cancer Patients
  • 15.9.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.9.6 Market Analysis
• 15.10 Korea
  • 15.10.1 By Cancer Incidence - Per Lakh of Total Population
  • 15.10.2 By Gender - Cancer Patients
    • 15.10.2.1 Male
    • 15.10.2.2 Female
  • 15.10.3 By Type - Cancer Patients, 2020
  • 15.10.4 By Mortality - Cancer Patients
  • 15.10.5 By Price Analysis - Cancer Pain Management Drug Price Per Capita
  • 15.10.6 Market Analysis

16. Emerging Therapies

• 16.1 Key Cross Competition
• 16.2 Tetrodotoxin: WexPharma
  • 16.2.1 Product description
  • 16.2.2 Other developmental activities
  • 16.2.3 Clinical development
  • 16.2.4 Safety and efficacy
• 16.3 Resiniferatoxin: Sorrento Therapeutics
  • 16.3.1 Product description
  • 16.3.2 Other developmental activities
  • 16.3.3 Clinical development
  • 16.3.4 Safety and efficacy
• 16.4 QIXLEEF: Tetra Bio-Pharma
  • 16.4.1 Product description
  • 16.4.2 Other developmental activities
  • 16.4.3 Clinical development
  • 16.4.4 Safety and efficacy

17. Company Analysis

• 17.1 Daiichi Sankyo Co., Ltd.
  • 17.1.1 Overview
  • 17.1.2 Business Strategy
  • 17.1.3 Financial Insight
• 17.2 Hisamitsu Pharmaceutical Co., Inc.
  • 17.2.1 Overview
  • 17.2.2 Business Strategy
  • 17.2.3 Financial Insight
• 17.3 Orexo AB
  • 17.3.1 Overview
  • 17.3.2 Business Strategy
  • 17.3.3 Financial Insight
• 17.4 Pfizer Inc
  • 17.4.1 Overview
  • 17.4.2 Business Strategy
  • 17.4.3 Financial Insight
• 17.5 Teva Pharmaceutical Industries Limited
  • 17.5.1 Overview
  • 17.5.2 Business Strategy
  • 17.5.3 Financial Insight
• 17.6 Sanofi
  • 17.6.1 Overview
  • 17.6.2 Business Strategy
  • 17.6.3 Financial Insight
• 17.7 Johnson & Johnson
  • 17.7.1 Overview
  • 17.7.2 Business Strategy
  • 17.7.3 Financial Insight
• 17.8 Eli Lilly
  • 17.8.1 Overview
  • 17.8.2 Business Strategy
  • 17.8.3 Financial Insight